Bio­gen sig­nals a big PhI­II fail­ure as the lead gene ther­a­py in their $800M Night­star buy­out goes down in flames

That $800 mil­lion buy­out of Night­star has turned in­to a bust for Bio­gen as the lead ther­a­py in the deal failed a piv­otal study, sig­nal­ing a se­vere set­back for the biotech’s am­bi­tions in gene ther­a­pies.

The big biotech put out the word af­ter the mar­ket closed on Mon­day that the gene ther­a­py they picked up in the deal for a de­gen­er­a­tive blind­ness called choroi­deremia failed the Phase III study, just a month af­ter their #2 drug in the deal al­so flopped in a mid-stage study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.